MiR-301a-3p Promotes Triple-Negative Breast Cancer Progression via PTEN Suppression in Tumor Cells and the Microenvironment.

阅读:2
作者:Lin Hai Yun, Li Guang Yan, Liang Wen Long, Wang Yao, Fu Bai Yang, Du Qi Guang, Zhang Yu Tong, Xu Zhong Kai, Cui He, Chen Xi, Fu Zheng, Zhang Jian Guo
BACKGROUND: Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, poses a severe threat to women's health. Adipose-derived stem cells (ADSCs) and microRNAs (miRNAs) critically influence tumor progression within the tumor microenvironment (TME), but the role of the miR-301a-3p/PTEN axis in TNBC requires elucidation. METHODS: PTEN expression and effects were assessed by comparing clinical TNBC tissues with adjacent normal tissues. Mechanisms were investigated using integrated dataset analysis, luciferase reporter assays, functional cell experiments (assessing malignant phenotypes), co-culture models with ADSCs, and in vivo tumor models. Molecular expression (PTEN, vascular endothelial growth factor A (VEGFA)) and pathway activity (phosphoinositide 3-kinase (PI3K)/AKT) were evaluated. RESULTS: MiR-301a-3p was upregulated in TNBC and directly bound PTEN's 3'-UTR to suppress its expression. Functionally, miR-301a-3p enhanced tumor cell malignancy. Tumor cell-derived exosomes transported miR-301a-3p to ADSCs in the TME, suppressing PTEN, activating the PI3K/AKT pathway, and upregulating VEGFA secretion. In vivo, modulating miR-301a-3p levels significantly altered tumor growth, PTEN expression, and VEGFA production in tumor and peritumoral tissues. CONCLUSION: MiR-301a-3p drives TNBC progression via exosome-mediated crosstalk with ADSCs, forming a PTEN/PI3K/AKT/VEGFA signaling axis. It represents a promising therapeutic target and novel biomarker with significant clinical value for TNBC treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。